Can any company pose a serious challenge to Eli Lilly in the weight-loss market?

If you’re weighing the option of Wegovy versus Zepbound for weight loss, here’s how the two medications compare in terms of ...

If you are among the 40% of people in the U.S. with obesity, one of the most powerful actions you can take for your health is working with your healthcare provider to treat it. Obesity is nothing to ...

CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill ...

A new agreement involving Medicare, Eli Lilly and Novo Nordisk could allow some eligible beneficiaries to access GLP-1 weight ...

Eli Lilly just released impressive study results for retatrutide, an investigational weight loss drug that targets three ...

In a reversal from last year, CVS will begin covering Eli Lilly's Zepbound and Foundayo in its standard prescription plan, a ...

Starting in July, Medicare beneficiaries may be able to get a GLP-1 prescription for weight loss for $50 a month. It’s a ...

CVS Caremark will start covering Eli Lilly's Foundayo and resume covering its Zepbound obesity drugs in the next several ...

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs ...

Inclusion of weight loss drugs on insurer formularies is a meaningful step towards expanding access. But having a product ...